 Silence Therapeutics plc NASDAQ: SLN has announced topline data from GEMINI Phase 1 study evaluating SLN124 for iron-loading anemia conditions, thalassemia, and myelodysplastic syndrome MDS. SLN124 is a short interfering ribonucleic acid siRNA that targets TMPRSS6. 